Incidence and survival from XXXX in Greenland is comparable to survival in the Nordic countries.

@entity1 @entity957 @entity1149 @entity2 @entity189 @entity151 @entity420
INTRODUCTION: Oncological treatment of @entity2 has been available in Greenland since 2004. We evaluated @entity1 characteristics and survival rates for the first six years of @entity2 treatment. METHODS: From September 2004 to August 2010, a total of 173 @entity1 with @entity2 were referred to treatment at Queen Ingrid's Hospital. On 1 February 2014, treatment results, survival, and prognostic variables were analysed. RESULTS: The mean age at diagnosis was 63 years. @entity1149 ( @entity1149 ) was diagnosed in 145 @entity1 (84%); 56% had @entity957 , 34% had @entity420 , 2% had large cell @entity189 and 8% had @entity1149 not otherwise specified (NOS). In all, 28 (16%) had @entity151 . A total of 142 @entity1 (82%) received treatment; 20 underwent surgery (ten stage Ib, one stage IIa, five stage IIb, four stage IIIa); palliative chemotherapy was given to 122 of the 142 treated @entity1 (86%). Of these, 36 @entity1 (30%) received second-line chemotherapy.The median survival of @entity1 undergoing primary lobectomy/pneumonectomy, palliative chemotherapy, and no treatment was 76.3 months, 11.8 months, and 2.0 months, respectively (p < 0.0001). CONCLUSION: Evaluation of the first six years of @entity2 treatment in Greenland revealed a disease incidence and survival comparable to those found in the Nordic countries. To further decrease mortality from @entity2 , health-care resources should continue to be allocated to the prevention and treatment of @entity2 in Greenland. FUNDING: not relevant. TRIAL REGISTRATION: not relevant.
